Sage Therapeutics, Inc. (NASDAQ:SAGE) Director George Golumbeski Buys 8,000 Shares

Sage Therapeutics, Inc. (NASDAQ:SAGEGet Rating) Director George Golumbeski acquired 8,000 shares of Sage Therapeutics stock in a transaction that occurred on Thursday, May 5th. The stock was acquired at an average cost of $31.45 per share, with a total value of $251,600.00. Following the completion of the purchase, the director now owns 8,000 shares in the company, valued at approximately $251,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ SAGE traded up $0.45 during midday trading on Monday, hitting $29.06. The company’s stock had a trading volume of 11,285 shares, compared to its average volume of 644,059. The business’s 50 day moving average is $33.89 and its two-hundred day moving average is $38.24. Sage Therapeutics, Inc. has a 12-month low of $28.17 and a 12-month high of $79.45.

Sage Therapeutics (NASDAQ:SAGEGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.06) by ($0.01). The business had revenue of $1.58 million during the quarter, compared to analyst estimates of $3.23 million. Sage Therapeutics had a negative return on equity of 27.23% and a negative net margin of 7,676.91%. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.64) EPS. Sell-side analysts predict that Sage Therapeutics, Inc. will post -8.43 earnings per share for the current year.

A number of equities analysts have recently issued reports on SAGE shares. Morgan Stanley dropped their price objective on shares of Sage Therapeutics from $61.00 to $57.00 and set an “equal weight” rating for the company in a research note on Thursday, March 10th. Berenberg Bank initiated coverage on shares of Sage Therapeutics in a report on Thursday, March 31st. They set a “hold” rating and a $37.00 price objective on the stock. The Goldman Sachs Group reduced their target price on shares of Sage Therapeutics to $96.00 and set a “buy” rating on the stock in a research note on Thursday, February 17th. StockNews.com began coverage on shares of Sage Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, SVB Leerink dropped their target price on shares of Sage Therapeutics from $60.00 to $50.00 and set a “market perform” rating on the stock in a report on Friday, February 25th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $62.95.

A number of hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Sage Therapeutics by 16.5% during the 3rd quarter. Wellington Management Group LLP now owns 6,769,933 shares of the biopharmaceutical company’s stock worth $299,976,000 after acquiring an additional 957,993 shares during the period. Bellevue Group AG grew its position in shares of Sage Therapeutics by 0.6% during the fourth quarter. Bellevue Group AG now owns 3,228,004 shares of the biopharmaceutical company’s stock worth $137,319,000 after buying an additional 19,000 shares in the last quarter. BlackRock Inc. raised its stake in Sage Therapeutics by 0.8% during the 3rd quarter. BlackRock Inc. now owns 2,874,555 shares of the biopharmaceutical company’s stock worth $127,371,000 after acquiring an additional 24,057 shares in the last quarter. State Street Corp grew its position in Sage Therapeutics by 9.7% during the 4th quarter. State Street Corp now owns 2,168,530 shares of the biopharmaceutical company’s stock worth $92,249,000 after purchasing an additional 192,578 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sage Therapeutics by 34.1% in the fourth quarter. JPMorgan Chase & Co. now owns 1,561,622 shares of the biopharmaceutical company’s stock valued at $66,433,000 after acquiring an additional 397,001 shares in the last quarter. Institutional investors own 84.40% of the company’s stock.

Sage Therapeutics Company Profile (Get Rating)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.

Further Reading

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.